NTRA - ナテラ （Natera Inc.） ナテラNTRAのチャート
NTRAの企業情報
| symbol | NTRA |
|---|---|
| 会社名 | Natera Inc （ナテラ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ナテラ(Natera Inc.)は診断会社である。同社は遺伝子検査サービスの発見・開発・商品化に従事する。同社は、母親から採血した胎児の染色体異常をスクリーニングするパノラマ非侵襲性出生前検査、キャリアの子供に渡される可能性のある多数の重度の遺伝病のキャリアステータスを決定するホライゾンキャリアスクリーニング、体外受精サイクル中に染色体異常または遺伝的遺伝的状態を分析して健康な子供になる可能性のある胚を選択するスペクトラムプレ移植遺伝子スクリーニングとスペクトラムプレ移植遺伝子診断、流産の原因を理解するために胎児の染色体を分析する受胎テストのAnora製品、並びに妊娠している母親の血液中の胎児性デオキシリボ核酸の断片と、疑わしい父親由来の血液サンプルを分析することにより父性を決定する非侵襲性父性検査を提供する。 ナテラは米国の遺伝子検査サ―ビス会社。主に出生前の遺伝子検査を提供する。体外受精において、着床前遺伝子スクリ―ニングを提供し、染色体異常や遺伝性遺伝子の状態を解析することで、受精胚の選択を可能にする。また、胎児の染色体異常を発見する検査や実父確定検査なども提供する。本社はカリフォルニア州サンカルロス。 natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the |
| 本社所在地 | 201 Industrial Road Suite 410 San Carlos CA 94070 USA |
| 代表者氏名 | Matthew Rabinowitz マシュー・ラビノウィッツ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Co-Founder |
| 電話番号 | +1 650-249-9090 |
| 設立年月日 | 37926 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 893人 |
| url | www.natera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ntra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -120.49200 |
| 終値（lastsale） | 21.31 |
| 時価総額（marketcap） | 1298720475.8 |
| 時価総額 | 時価総額（百万ドル） 1225.587 |
| 売上高 | 売上高（百万ドル） 235.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1265.723 |
| 当期純利益 | 当期純利益（百万ドル） -139.31800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Natera Inc revenues increased 23% to $125.4M. Net loss increased 7% to $66.7M. Revenues reflect United States segment increase of 21% to $107M Europe Middle East India Africa segment increase of 91% to $13.1M. Higher net loss reflects Interest and other income decrease from $887K (income) to $3.8M (expense) Interest expense increase from $401K to $4.9M (expense). |
NTRAのテクニカル分析
NTRAのニュース
Natera Announces Data from the ProActive Study that Supports Prospera Kidney as an Early Indicator of Transplant Rejection 2023/06/04 23:08:00 Wallstreet:Online
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection 2023/06/04 23:08:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor-derived cell-free DNA (dd-cfDNA) study evaluating Natera’s Prospera test for the detection of rejection in kidney transplant patients, as well as additional presentations
Natera: Q1 Results Reflect Triumphs In Prenatal, Transplant, And Cancer Testing 2023/05/19 15:54:31 Seeking Alpha
Natera reported outstanding Q1 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. Read more here.
Natera Reexamined 2023/05/17 16:37:04 Seeking Alpha
Today, we revisit genetic testing concern Natera. NTRA stock is up over 30% in 2023. Revenue growth is good, but what about profitability? Click here for more.
Invitae to appeal verdict in Natera patent case 2023/05/15 20:59:32 Seeking Alpha
Invitae (NVTA) said it will appeal a verdict in a patent case in a federal court in Delaware that found in favor of Natera (NTRA). Read more here.
Natera, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:NTRA) 2022/08/05 21:44:25 Seeking Alpha
The following slide deck was published by Natera, Inc.
Natera: Q2 Earnings Snapshot 2022/08/04 22:37:20 mySA
AUSTIN, Texas (AP) _ Natera Inc. (NTRA) on Thursday reported a loss of $145.2 million in its second quarter. On a per-share basis, the Austin, Texas-based company said it had a loss of $1.50. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.47 per share. The genetic testing company posted revenue of $198.2 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $194.1 million. Natera expects full-year revenue in the range of $805 million to $825 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NTRA at https://www.zacks.com/ap/NTRA
Natera GAAP EPS of -$1.50 in-line, revenue of $198.2M beats by $4.53M 2022/08/04 20:21:54 Seeking Alpha
Natera press release (NTRA): Q2 GAAP EPS of -$1.50 in-line.Revenue of $198.2M (+39.5% Y/Y) beats by $4.53M.Natera anticipates 2022 total revenue of $805 million to $825 million;…
Natera Reports Second Quarter 2022 Financial Results 2022/08/04 20:05:00 PR Newswire
AUSTIN, Texas, Aug. 4, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments &…
Natera Q2 2022 Earnings Preview (NASDAQ:NTRA) 2022/08/03 21:35:51 Seeking Alpha
Natera (NTRA) is scheduled to announce Q2 earnings results on Thursday, August 4th, after market close.The consensus EPS Estimate is -$1.50 and the consensus Revenue Estimate is…
Natera Inc. (NASDAQ:NTRA) Shares Plunged -8.78% In A Week – But Will They Keep Going Up? 2022/07/01 12:00:00 Marketing Sentinel
In last trading session, Natera Inc. (NASDAQ:NTRA) saw 1.04 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $35.44 trading at -$1.43 or -3.88% at ring of the bell on the day assigns it a market valuation of $3.20B. That closing price of NTRA’s stock is at … Natera Inc. (NASDAQ:NTRA) Shares Plunged -8.78% In A Week – But Will They Keep Going Up? Read More »
The Worldwide Carrier Screening Industry is Expected to Reach $3.64 Billion by 2030 2022/06/29 09:53:00 GlobeNewswire
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com''s offering. The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques. Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings.
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Natera, Inc. (NTRA) Investors of Class Action and Encourages Investors to Actively Participate 2022/06/27 15:00:00 Business Wire
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Natera, Inc. (
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm 2022/06/27 12:30:00 PR Newswire
LOS ANGELES, June 27, 2022 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of…